Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

Baricitinib helps with early hair regrowth in people with alopecia areata.

Early diagnosis of pseudopelade of Brocq in men is crucial to prevent permanent hair loss.

This study defines two types of RDEB wounds, chronic open and recurrent, and finds that patient self-reports on wound size correlate well with investigator measurements when complemented by serial photography.

This abstract discusses treatment options for benign prostatic hyperplasia and provides no new clinical results.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

In this case study, a three-year-old Labrador with canine atopic dermatitis showed significant improvement in pruritus and skin lesions after treatment with oclacitinib and supportive therapy over a one-month follow-up.

In this study, conducted during the 22nd FIFA World Cup in Qatar, doping control analysis of 1612 samples showed negative results for prohibited substances, except for two instances each of codeine and carboxy finasteride.

This article discusses vaccination coverage for BCG, Polio, and Hepatitis B in Juiz de Fora using SUS data and reports no new results; the authors aim to hypothesize reasons for coverage variation.

This case study describes a 17-year-old girl initially thought to be experiencing a Crohn disease exacerbation, but ultimately found to have a trichobezoar causing small bowel obstruction.

This article defines body dysmorphic disorder as excessive concern over perceived physical defects that cause distress and affect social or functional activities, but it reports no new results.

This study employed multiple linear regressions to analyze hydantoin analogues and produced a model with strong predictive abilities for designing new androgen receptor modulators.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This study found that Middle Eastern patients with epidermolysis bullosa show specific correlations between their genetic variants and clinical features, which may aid in diagnosis and genetic counseling.

This study found that BOTOX doses of 75–100 U effectively reduce postvoiding residual urine and detrusor pressure in patients with detrusor sphincter dyssynergia.

Photobiomodulation did not significantly improve hair density in dogs with alopecia X.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

CD206+ macrophages are crucial for hair growth in alopecia areata treatment.

This review highlights brimonidine’s potential as a dermatological agent, noting its ability to improve rosacea-related facial redness and its effectiveness in various other skin conditions due to its vasoconstrictive and anti-inflammatory actions, with minimal systemic absorption and a favorable safety profile for long-term use.

In this study, BCC therapy reduced oxidative stress and cell damage in cardiomyocyte cells, suggesting it may serve as a new treatment alternative for heart disease.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This study developed a novel treatment method using carbon dots from Cinnamomum burmannii leaves, which improved hair regeneration and thickness in an AGA mouse model by promoting cell proliferation, angiogenesis, and reducing inflammation through multiple signaling pathways.

This study found significant upregulation of IDO-1 and IDO-2 in human basal cell carcinomas, suggesting that IDO production may confer immune privilege characteristics to the tumors, potentially impacting their growth.

This study validated the Egyptian Arabic version of the Skindex-16 and found that skin conditions significantly impacted patients' quality of life, particularly in the emotional domain.

This study describes Pseudopelade of Brocq as a rare and enigmatic scarring alopecia characterized by irregular hair loss patterns on the scalp, requiring exclusion of other conditions like lichen planopilaris and discoid lupus erythematosus for a specific diagnosis.

This case study reports a new LAMB3 mutation linked to junctional epidermolysis bullosa with severe urinary tract stenosis, outlining treatment challenges and expanding knowledge of EB-related urological complications.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.